Table 2.
Prognostic Factor Analysis for Southwest Oncology Group Protocol S0016: Prognostic Factor Analysis
| Model | HR | 95% CI | P |
|---|---|---|---|
| Outcome, PFS | |||
| LDH alone | 1.59 | 1.17 to 2.17 | .003 |
| Serum-β2 M alone | 1.70 | 1.27 to 2.28 | .0004 |
| Serum-β2 M and LDH* | 2.24 | 1.51 to 3.31 | < .0001 |
| FLIPI* | 2.41 | 1.63 to 3.56 | < .0001 |
| Outcome, OS | |||
| LDH alone | 2.46 | 1.49 to 4.07 | .0004 |
| Serum-β2 M alone | 2.22 | 1.31 to 3.76 | .003 |
| Serum-β2 M and LDH* | 3.95 | 2.01 to 7.78 | < .0001 |
| FLIPI* | 3.81 | 1.92 to 7.54 | .0001 |
Abbreviations: FLIPI, Follicular Lymphoma International Prognostic Index; HR, hazard ratio; LDH, lactate dehydrogenase; PFS, progression-free survival; OS, overall survival.
*
HRs show comparisons between high- versus low-risk groups.